News & Events

RePEAT research project showcases scale of digitisation of 19th century bog maps University of Galway has announced the launch of the All-Ireland Peatlands Centre of Excellence to lead research and policy development on restoration and conservation of bogland.  The Centre has been established at the University’s Ryan Institute to help address critical challenges linked to peatlands, including decarbonisation, biodiversity loss, just transition and cultural heritage.  Along with academic research and policy development, it will also serve as a hub for innovation and training in relation to protection of peatlands on the island of Ireland and overseas.  The establishment of the All-Ireland Peatlands Centre of Excellence builds on a strong collaborative ethos among multiple universities, government agencies and community groups.  It also follows on from the RePEAT project, a research collaboration involving University of Galway and Trinity College Dublin which identified former peatlands areas that are suitable for alternative management and informs national bog rewetting projects to reduce greenhouse gas emissions.  Using Bog Commissioner maps from the 19th century which were originally designed to facilitate drainage, RePEAT researchers digitised the maps and turned them against their initial purpose in order to establish the original baseline extent of peatlands. The maps recorded the large-scale survey of more than 1 million acres of bogs between 1810 and 1814.   The RePEAT project was funded by the Department of Agriculture Food and Marine and the Environmental Protection Agency.  Dr Terry Morley, Lead of the new All-Ireland Peatlands Centre of Excellence and researcher on RePEAT project, Ryan Institute, University of Galway, said: “The All-Ireland Peatlands Centre of Excellence will bring together scientists, policymakers, landowners, and communities.  “We hope that through this new Centre of Excellence we will be able to strengthen national capacity for sustainable peatland management and ensure long-term environmental and societal benefits from restoration and conservation.  “University of Galway is uniquely situated to lead this centre, with blanket and raised bogs at our doorstep and broad interdisciplinary peatland research expertise.”  Dr John Connolly, a researcher on the project from Trinity College Dublin, said: “The RePEAT project has identified more than 200,000 hectares of former peatland, which is now in other land uses. These areas represent emissions many times higher than their baseline and can be used to identify areas that may be suitable for restoration and rewetting under Ireland’s Climate Action Plan.”  A special showcase outlining the findings of the RePEAT research project is being hosted in the Orbsen Building on the University of Galway campus from Monday December 15th-19th while a public lecture will be held on Thursday, December 18th at 5pm in the Michael D Higgins Auditorium.  Ends

New research into the arrangement of sugar chains or ‘glycans’ in the cells of the spine has shed light for the first time on the critical role it plays in the complex process of disc degeneration.   Researchers at CÚRAM - Research Ireland Centre for Medical Devices at University of Galway, together with a team of international colleagues, carried out a comprehensive investigation into the different characteristics of glycans in healthy and degenerated intervertebral discs.   It is the first time that the whole human disc glycome in the spine - the entire set of sugar chains that modify human proteins and lipids - have been analysed in this way.    Intervertebral disc (IVD) degeneration is a major cause of low back pain, a significant global health issue. While glycosylation is critical for cellular signalling and inflammation, its malfunction can lead to diseases and its role in IVD degeneration has remained poorly understood until the research was conducted.   Dr Kieran Joyce, first author of the paper, said: “From this research, we now know which sugars are expressed in the degenerated or diseased disc states, so we can design therapies to target this.   “We observed distinct alterations in glycan expression, notably an overabundance of sialic acid on the surface of the cells in degenerated discs and decreased branching, which are associated with IVD degeneration. These observed differences have implications for regulating inflammatory responses and other cellular activities.”   Professor Abhay Pandit, Scientific Director of CÚRAM and senior author of the research paper, said: “Our findings suggest that there is therapeutic potential in using biomaterial systems to intervene and alter the way proteins and glycans attach to each other to reduce inflammation associated with IVD degeneration. This research significantly advances our knowledge of the glycomic mechanisms underlying IVD degeneration and opens new avenues for developing therapies to restore disc physiology.”   The finding of the research have been published in Advanced Science and can be accessed at https://advanced.onlinelibrary.wiley.com/doi/10.1002/advs.202506669?af=R.   The project was carried out by CÚRAM researchers at University of Galway in collaboration with colleagues at Maynooth University, University College Dublin, the National Institute for Bioprocessing Research and Training (NIBRT), the Medical University of South Carolina and the Institute of Chemical Technologies and Analytics in Austria.   Ends

University of Galway’s Institute for Clinical Trials has been awarded the 2025 Collaboration in Medtech Award at the Irish Medtech Awards.  The accolade recognises the Institute’s outstanding leadership in advancing early-stage medtech innovation through high-impact clinical partnerships, including the establishment of the Hypercare initiative to supports partners in the clinical trials approval process.   It is the second year in a row in which University of Galway has won the Collaboration in Medtech Award.   Established in 2023, the Institute for Clinical Trials is focused on transformation of the clinical research landscape in Ireland by creating an environment where scientific advances are translated into improved care for patients.  The 2025 Collaboration in Medtech Award was secured for the Institute’s Hypercare initiative, which has been developed to transform how early-stage medtech trials are delivered in Ireland. The initiative is a national pilot, designed to support  industry collaborators in navigating complex approval processes for a clinical trial, from ethics and regulatory submission to system requirements of the Health Service Executive, through to initial patient enrolment.   Aligned with the mission of the Institute for Clinical Trials, this project drives excellence, inclusivity, and need-driven research to improve global health outcomes. Clinical trials increase the opportunities of patients to have early access to innovative treatments that could improve, extend or even save their lives.  Encouraging more research must be a priority for those bodies charged with improving the nation’s health and the Hypercare initiative seeks to support this by ensuring Ireland is a location of choice for early feasibility/phase MedTech trial conduct and delivery. The Hypercare project aims to highlight positive changes in the delivery of clinical research in Ireland, attracting further interest and investment from MedTech stakeholders nationally and internationally.             Professor Fidelma Dunne, Director of the Institute for Clinical Trials at University of Galway, said: "It is a real honour for the Institute to win the 2025 Collaboration in Medtech Award. Collaboration is at the heart of everything we do at the Institute for Clinical Trials, and this recognition reflects the commitment of our team and our partners.   “The Hypercare initiative stands out as the model for academic–industry collaboration, advancing innovation while upholding the highest clinical and regulatory standards. By working closely with innovators, from early-stage start-ups to global leaders, we are making great strides in demonstrating where Ireland can lead in the world of clinical trials as well as accelerating the delivery of new technologies that can truly improve patient outcomes at home and across the globe."            Hypercare has successfully supported four companies to date through the pilot, two of which have launched a first-in-human use of their device in Ireland – Medtronic and Intervene.   By bringing together clinical expertise, regulatory guidance, and real-world testing, the Institute helps partners move through approvals in a more structured and predictable process and therefore more quickly through early clinical validation with the hope of bringing new helathcare solutions to patients in Ireland and beyond.  The Collaboration in Medtech Award celebrates the Institute’s success in forging partnerships that strengthen Ireland’s position in medtech and support a more collaborative, efficient, and innovative approach to clinical research.  Irish Medtech, the Ibec group that represents the medtech sector, Enterprise Ireland and IDA Ireland held the awards as part of Medtech Rising, an annual conference for the sector held this year at The Galmont Hotel in Galway.  Ends